Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Neoantigen
100%
Natural Killer Cells
87%
Tumor
68%
T Cells
60%
Human Immunodeficiency Virus Type 1 (HIV-1)
49%
CD4+ T
48%
Infected Cells
37%
Immune Checkpoint Therapy
36%
Metastatic Non-small Cell Lung Cancer
34%
Cell Toxicity
32%
Tumor Treating Fields Therapy
32%
MHC-I
31%
CD8+ T Cells
30%
Tumor Rejection
29%
Checkpoint Blockade Immunotherapy
29%
Lysis
29%
HIV-infected Cells
28%
Cancer Immunotherapy
27%
Tumor Immunity
26%
Cancer Therapy
25%
HIV-infected Patients
25%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
23%
NKG2D
23%
Mutational Load
21%
Radiation Effects
21%
Immunotherapeutics
21%
Circulating Tumor DNA (ctDNA)
21%
Phenotypic Heterogeneity
21%
Immune Checkpoint
21%
High-dimensional Data Analysis
21%
Intratumoural
21%
Tumor-specific mutant Antigens
21%
CDC1
21%
Tumor-specific
21%
Immunogenicity
21%
Immune System
20%
Immune Checkpoint Inhibitors
19%
Tumor Cells
18%
Tumor Antigen
18%
Epitope
17%
Synergize
17%
Tumor Treating Fields
17%
Small Cell Lung Cancer
16%
Cell-mediated
16%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
16%
T Cell Response
15%
Cancer Genomics
15%
Previously Treated
15%
Phase I Study
15%
Conventional Dendritic Cells
14%
Immunology and Microbiology
Neoantigen
98%
T Cell
88%
Natural Killer Cell
84%
T-Helper Cell
67%
Human Immunodeficiency Virus 1
64%
Human Immunodeficiency Virus
61%
Cytotoxic T-Cell
53%
Immunotherapy
36%
Tumor Immunity
25%
Vpr
23%
Tumor Rejection
22%
Antigen
22%
Vpu
21%
Myeloid
21%
Mutational Load
21%
NKG2D
20%
Immunogenicity
18%
Tumor Cell
18%
Cancer Immunotherapy
17%
CX3CR1
17%
Immune System
15%
CD4
15%
Immune Response
14%
Tumor-Associated Macrophage
14%
Macrophage
14%
Tumor Antigen
14%
Bioinformatics
14%
Dendritic Cell
14%
Human Immunodeficiency Virus Infection
13%
Major Histocompatibility Complex
13%
Target Cell
13%
In Vitro
13%
Cytolysis
12%
Epitope
12%
Degranulation
12%
Effector Cell
11%
B Cell
10%
Protein Binding
10%
Natural Killer Cell Mediated Cytotoxicity
10%
CD155
10%
DNA Damage Response
10%
Sarcoma Cell Line
10%
Cell Antigen
10%
Host Cell
10%
Regulatory T Cell
10%
Immune Escape
10%
Programmed Death-Ligand 1
10%
Vpx
10%
Ion Mobility Mass Spectrometry
10%
Susceptibility
10%
Medicine and Dentistry
Non Small Cell Lung Cancer
70%
Tumor Treating Fields
32%
Platinum
27%
Circulating Tumor DNA
21%
Overall Survival
20%
Immune Checkpoint Inhibitor
17%
Systemic Therapy
15%
Diseases
13%
Small Cell Lung Cancer
13%
Lung Cancer
12%
Atezolizumab
11%
Cancer Therapy
10%
Diffuse Large B-Cell Lymphoma
10%
Brentuximab Vedotin
10%
Chemoradiotherapy
10%
Biological Marker
10%
Ramucirumab
10%
Lenalidomide
10%
Tumor Infiltrating Lymphocyte
10%
Nintedanib
10%
Body Mass Index
10%
Progression Free Survival
10%
Malignant Neoplasm
9%
Adverse Event
9%
Platelet Derived Growth Factor Receptor
7%
Histology
6%
Lung
5%
Treatment Option
5%
Docetaxel
5%
Immunotherapy
5%